Circulation Research, Vol 63, 1036-1043, Copyright © 1988 by American Heart Association

ARTICLES

Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine

GD Lopaschuk, SR Wall, PM Olley and NJ Davies
Department of Pediatrics, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Fatty acids are known to increase the severity of injury during acute myocardial ischemia. In this study, we determined the effects of a carnitine palmitoyltransferase I inhibitor, ethyl 2-[6-(4- chlorophenoxy)hexyl]oxirane-2-carboxylate (Etomoxir) on reperfusion recovery of fatty acid perfused hearts. Following a 25-minute period of global ischemia, isolated working hearts reperfused with 1.2 mM palmitate, 11 mM glucose exhibited depressed function compared to hearts perfused with 11 mM glucose alone. A low dose of Etomoxir (10(- 9) M) decreased long chain acylcarnitine and long chain acyl-coenzyme A (CoA) levels but did not prevent depressed function. In contrast, a high dose of Etomoxir (10(-6) M) prevented the palmitate-induced depression of function but did not decrease myocardial long chain acylcarnitine or long chain acyl-CoA levels. At this high dose of Etomoxir, oxygen consumption per unit work was decreased during reperfusion recovery, and ATP and creatine-phosphate levels were significantly higher after reperfusion. In aerobic hearts not subjected to ischemia, Etomoxir (10(-6) M) increased glucose oxidation both in the presence and absence of palmitate, while 10(-9) M Etomoxir had no effect. In these aerobic hearts, only the low dose of Etomoxir decreased long chain acylcarnitine and long chain acyl-CoA levels. These data demonstrate that Etomoxir (10(-6) M) increases functional recovery of fatty acid perfused ischemic hearts. This protection is unrelated to changes in levels of long chain acylcarnitines but may be due to increased glucose use by the reperfused heart, resulting in decreased oxygen consumption per unit work.

This article has been cited by other articles:

				A. D. Hafstad, A. M. Khalid, O.-J. How, T. S. Larsen, and E. Aasum Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1288 - E1294. [Abstract] [Full Text] [PDF]

				N. Sambandam, D. Morabito, C. Wagg, B. N. Finck, D. P. Kelly, and G. D. Lopaschuk Chronic activation of PPAR{alpha} is detrimental to cardiac recovery after ischemia Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H87 - H95. [Abstract] [Full Text] [PDF]

				L. Lee, J. Horowitz, and M. Frenneaux Metabolic manipulation in ischaemic heart disease, a novel approach to treatment Eur. Heart J., April 2, 2004; 25(8): 634 - 641. [Abstract] [Full Text] [PDF]

				M. Kuang, M. Febbraio, C. Wagg, G. D. Lopaschuk, and J. R.B. Dyck Fatty Acid Translocase/CD36 Deficiency Does Not Energetically or Functionally Compromise Hearts Before or After Ischemia Circulation, March 30, 2004; 109(12): 1550 - 1557. [Abstract] [Full Text] [PDF]

				H. Taegtmeyer Improving Energy Metabolism in the Postischemic Heart-The Story of GIK Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 67 - 76. [Abstract] [PDF]

				R. K. Kudej, L. T. White, A. B. Kudej, S. F. Vatner, and E. D. Lewandowski Brief Increase in Carbohydrate Oxidation After Reperfusion Reverses Myocardial Stunning in Conscious Pigs Circulation, November 26, 2002; 106(22): 2836 - 2841. [Abstract] [Full Text] [PDF]

				N. F. Gilbert, P. E. Meyer, M. P. Tauriainen, R. Y. Chao, J. B. Patel, C. R. Malloy, and M. E. Jessen Effects of hypothermia on myocardial substrate selection Ann. Thorac. Surg., October 1, 2002; 74(4): 1208 - 1212. [Abstract] [Full Text] [PDF]

				S. L. Longnus, R. B. Wambolt, R. L. Barr, G. D. Lopaschuk, and M. F. Allard Regulation of myocardial fatty acid oxidation by substrate supply Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1561 - H1567. [Abstract] [Full Text] [PDF]

				R. Ramasamy, Y. Hwang, S. Bakr, and S. R. Bergmann Protection of ischemic hearts perfused with an anion exchange inhibitor, DIDS, is associated with beneficial changes in substrate metabolism Cardiovasc Res, August 1, 2001; 51(2): 275 - 282. [Abstract] [Full Text] [PDF]

				R. L. Dobbins, L. S. Szczepaniak, B. Bentley, V. Esser, J. Myhill, and J. D. McGarry Prolonged Inhibition of Muscle Carnitine Palmitoyltransferase-1 Promotes Intramyocellular Lipid Accumulation and Insulin Resistance in Rats Diabetes, January 1, 2001; 50(1): 123 - 130. [Abstract] [Full Text]

				C. Montessuit, I. Papageorgiou, I. Tardy-Cantalupi, N. Rosenblatt-Velin, and R. Lerch Postischemic recovery of heart metabolism and function: role of mitochondrial fatty acid transfer J Appl Physiol, July 1, 2000; 89(1): 111 - 119. [Abstract] [Full Text] [PDF]

				P. E. Meyer, M. E. Jessen, J. B. Patel, R. Y. Chao, C. R. Malloy, and D. M. Meyer Effects of storage and reperfusion oxygen content on substrate metabolism in the isolated rat lung Ann. Thorac. Surg., July 1, 2000; 70(1): 264 - 269. [Abstract] [Full Text] [PDF]

				K. Yoshisue, Y. Yamamoto, K.-I. Yoshida, M. Saeki, Y. Minami, Y. Esumi, and Y. Kawaguchi Pharmacokinetics and Biological Fate of 3-(2,2,2-Trimethylhydrazinium)Propionate Dihydrate (MET-88), a Novel Cardioprotective Agent, in Rats Drug Metab. Dispos., June 1, 2000; 28(6): 687 - 694. [Abstract] [Full Text]

				D. Portilla, G. Dai, J. M. Peters, F. J. Gonzalez, M. D. Crew, and A. D. Proia Etomoxir-induced PPARalpha -modulated enzymes protect during acute renal failure Am J Physiol Renal Physiol, April 1, 2000; 278(4): F667 - F675. [Abstract] [Full Text] [PDF]

				P. H. McNulty, D. Jagasia, G. W. Cline, C. K. Ng, J. M. Whiting, P. Garg, G. I. Shulman, and R. Soufer Persistent Changes in Myocardial Glucose Metabolism In Vivo During Reperfusion of a Limited-Duration Coronary Occlusion Circulation, February 29, 2000; 101(8): 917 - 922. [Abstract] [Full Text] [PDF]

				E. P Brass and W. R Hiatt Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease Vascular Medicine, February 1, 2000; 5(1): 55 - 59. [Abstract] [PDF]

				M. Kuwajima, H. Harashima, M. Hayashi, S. Ise, M. Sei, K.-m. Lu, H. Kiwada, Y. Sugiyama, and K. Shima Pharmacokinetic Analysis of the Cardioprotective Effect of 3-(2,2,2-Trimethylhydrazinium) Propionate in Mice: Inhibition of Carnitine Transport in Kidney J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 93 - 102. [Abstract] [Full Text]

				K. Kato, D. C. Chapman, H. Rupp, A. Lukas, and N. S. Dhalla Alterations of heart function and Na+-K+-ATPase activity by etomoxir in diabetic rats J Appl Physiol, March 1, 1999; 86(3): 812 - 818. [Abstract] [Full Text] [PDF]

				N. Trueblood and R. Ramasamy Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts Am J Physiol Heart Circ Physiol, July 1, 1998; 275(1): H75 - H83. [Abstract] [Full Text] [PDF]

				B. Liu, A. S. Clanachan, R. Schulz, and G. D. Lopaschuk Cardiac Efficiency Is Improved After Ischemia by Altering Both the Source and Fate of Protons Circ. Res., November 1, 1996; 79(5): 940 - 948. [Abstract] [Full Text]

				N. Kudo, A. J. Barr, R. L. Barr, S. Desai, and G. D. Lopaschuk High Rates of Fatty Acid Oxidation during Reperfusion of Ischemic Hearts Are Associated with a Decrease in Malonyl-CoA Levels Due to an Increase in 5`-AMP-activated Protein Kinase Inhibition of Acetyl-CoA Carboxylase J. Biol. Chem., July 21, 1995; 270(29): 17513 - 17520. [Abstract] [Full Text] [PDF]